Skip to main content
Top
Published in: Cancer Microenvironment 2/2012

01-08-2012 | Original Paper

Clinical and Biological Implications of the Tumor Microenvironment

Author: David Tarin

Published in: Cancer Microenvironment | Issue 2/2012

Login to get access

Abstract

In normal tissues and organs, the activities of the constituent cells are strictly restricted to the tasks assigned to them during development. In addition they (with the exception of leukocytes) remain inflexibly confined to their territorial domains by regulatory interactions with their neighbors. This creates specialized local micro-environments in which structure and function are orderly, stable and tightly controlled by feed-back loops, within interacting regulatory networks. This system has considerable ability to adapt to changing conditions. In contrast, the microenvironment in regions where tumors are forming and expanding is characterized by progressive loss of specialized or differentiated cellular functions, disorderly molecular signals, degeneration of microscopical organ structure. This, coupled with the traffic of cells into and out of the tumor, often culminating in local invasion and metastasis to other organs. The nature of these disturbed molecular and cellular interactions is, by definition, highly unstable and increasingly unpredictable as time passes. It also varies between different tumors, sometimes even leading to regression. However, systematic analysis of this dysfunction in the tumor microcosm, using multiple modern research techniques, has revealed that all actively growing primary and secondary neoplasms share an absolute dependency upon support from adjacent non-neoplastic cells of the host. This support, in turn, continuously depends upon dynamic interplay between tumor and host cell populations, via signaling molecules and surface receptors in the tumor microenvironment. Such interplay determines the fate of the growing neoplasm. Such information, described and evaluated in this article, provides important new insights into the etiology of carcinogenesis and how tumor growth, invasion and metastasis might be therapeutically arrested. The facts and concepts assembled below, regarding the cancer microenvironment, demonstrate how modern molecular findings reveal the impact of the wide range of cancer diseases upon the internal cellular, tissue and organ environments of the whole individual and how this applies to designing new work to improve human cancer diagnosis and treatment. The article discusses several specific types of experimentally-induced and clinically common cancers to derive principles useful for interpreting events in the tumor microenvironment, which apply to cancers in general and especially to human malignant disease.
Literature
1.
go back to reference Orr J (1938) Changes antecedent to tumour formation during the treatment of mouse skin with carcinogenic hydrocarbons. J Pathol Bacteriol 46:495–515CrossRef Orr J (1938) Changes antecedent to tumour formation during the treatment of mouse skin with carcinogenic hydrocarbons. J Pathol Bacteriol 46:495–515CrossRef
2.
go back to reference Tarin D (1972) Morphological studies on the mechanism of carcinogenesis. In: Tarin D (ed) Tissue interactions in carcinogenesis. Academic, London, pp 227–289 Tarin D (1972) Morphological studies on the mechanism of carcinogenesis. In: Tarin D (ed) Tissue interactions in carcinogenesis. Academic, London, pp 227–289
3.
go back to reference Tarin D (1972) Tissue interactions in morphogenesis, morphostasis and carcinogenesis. J Theor Biol 34(1):61–72PubMedCrossRef Tarin D (1972) Tissue interactions in morphogenesis, morphostasis and carcinogenesis. J Theor Biol 34(1):61–72PubMedCrossRef
4.
go back to reference Kratochwil K (1972) Tissue interaction during embryonic development. In: Tarin D (ed) Tissue interactions in carcinogenesis. Academic, London, pp 1–47 Kratochwil K (1972) Tissue interaction during embryonic development. In: Tarin D (ed) Tissue interactions in carcinogenesis. Academic, London, pp 1–47
5.
go back to reference Tarin D (1967) Sequential electron microscopical study of experimental mouse skin carcinogenesis. Int J Cancer 2(3):195–211PubMedCrossRef Tarin D (1967) Sequential electron microscopical study of experimental mouse skin carcinogenesis. Int J Cancer 2(3):195–211PubMedCrossRef
6.
go back to reference Tarin D (1969) Fine structure of murine mammary tumours: the relationship between epithelium and connective tissue in neoplasms induced by various agents. Br J Cancer 23(2):417–425PubMedCrossRef Tarin D (1969) Fine structure of murine mammary tumours: the relationship between epithelium and connective tissue in neoplasms induced by various agents. Br J Cancer 23(2):417–425PubMedCrossRef
7.
go back to reference Billingham RE, Orr JW, Woodhouse DL (1951) Transplantation of skin components during chemical carcinogenesis with 20-methylcholanthrene. Br J Cancer 5(4):417–432PubMedCrossRef Billingham RE, Orr JW, Woodhouse DL (1951) Transplantation of skin components during chemical carcinogenesis with 20-methylcholanthrene. Br J Cancer 5(4):417–432PubMedCrossRef
8.
go back to reference Orr J, Spencer A (1972) Transplantation studies of the role of the stroma in epidermal carcinogenesis. In: Tarin D (ed) Tissue Interactions in carcinogenesis. Academic, London, pp 291–303 Orr J, Spencer A (1972) Transplantation studies of the role of the stroma in epidermal carcinogenesis. In: Tarin D (ed) Tissue Interactions in carcinogenesis. Academic, London, pp 291–303
9.
go back to reference Brand KG, Buoen LC, Johnson KH, Brand I (1975) Etiological factors, stages, and the role of the foreign body in foreign body tumorigenesis: a review. Cancer Res 35(2):279–286PubMed Brand KG, Buoen LC, Johnson KH, Brand I (1975) Etiological factors, stages, and the role of the foreign body in foreign body tumorigenesis: a review. Cancer Res 35(2):279–286PubMed
10.
go back to reference Tarin D (1972) Tissue interactions in carcinogenesis. Academic, London Tarin D (1972) Tissue interactions in carcinogenesis. Academic, London
12.
go back to reference Tarin D (2011) Cell and tissue interactions in carcinogenesis and metastasis and their clinical significance. Semin Cancer Biol 21(2):72–82 Tarin D (2011) Cell and tissue interactions in carcinogenesis and metastasis and their clinical significance. Semin Cancer Biol 21(2):72–82
13.
go back to reference Tarin D (2011) Inappropriate gene expression in human cancer and its far-reaching biological and clinical significance. Cancer Metastasis Rev Tarin D (2011) Inappropriate gene expression in human cancer and its far-reaching biological and clinical significance. Cancer Metastasis Rev
14.
go back to reference Spemann H (1938) Embryonic induction and development. In. Yale University Press, New Haven Spemann H (1938) Embryonic induction and development. In. Yale University Press, New Haven
15.
go back to reference Tarin D (1972) Tissue interactions and the maintenance of histological structure in adults. In: Tarin D (ed) Tissue interactions in carcinogenesis. Academic, London, pp 81–93 Tarin D (1972) Tissue interactions and the maintenance of histological structure in adults. In: Tarin D (ed) Tissue interactions in carcinogenesis. Academic, London, pp 81–93
16.
go back to reference Warburton D, Wuenschell C, Flores-Delgado G, Anderson K (1998) Commitment and differentiation of lung cell lineages. Biochem Cell Biol 76(6):971–995PubMedCrossRef Warburton D, Wuenschell C, Flores-Delgado G, Anderson K (1998) Commitment and differentiation of lung cell lineages. Biochem Cell Biol 76(6):971–995PubMedCrossRef
17.
go back to reference Beers MF, Morrisey EE (2011) The three R’s of lung health and disease: repair, remodeling, and regeneration. J Clin Invest 121(6):2065–2073PubMedCrossRef Beers MF, Morrisey EE (2011) The three R’s of lung health and disease: repair, remodeling, and regeneration. J Clin Invest 121(6):2065–2073PubMedCrossRef
18.
go back to reference Saxén L (1972) Interactive mechanisms in morphogenesis. In: Tarin D (ed) Tissue interactions in carcinogenesis. Academic, London, pp 49–80 Saxén L (1972) Interactive mechanisms in morphogenesis. In: Tarin D (ed) Tissue interactions in carcinogenesis. Academic, London, pp 49–80
19.
go back to reference Nagatomo T, Ohga S, Takada H et al (2004) Microarray analysis of human milk cells: persistent high expression of osteopontin during the lactation period. Clin Exp Immunol 138(1):47–53PubMedCrossRef Nagatomo T, Ohga S, Takada H et al (2004) Microarray analysis of human milk cells: persistent high expression of osteopontin during the lactation period. Clin Exp Immunol 138(1):47–53PubMedCrossRef
20.
go back to reference Nemir M, Bhattacharyya D, Li X, Singh K, Mukherjee AB, Mukherjee BB (2000) Targeted inhibition of osteopontin expression in the mammary gland causes abnormal morphogenesis and lactation deficiency. J Biol Chem 275(2):969–976PubMedCrossRef Nemir M, Bhattacharyya D, Li X, Singh K, Mukherjee AB, Mukherjee BB (2000) Targeted inhibition of osteopontin expression in the mammary gland causes abnormal morphogenesis and lactation deficiency. J Biol Chem 275(2):969–976PubMedCrossRef
21.
go back to reference Kyriakides TR, Bornstein P (2003) Matricellular proteins as modulators of wound healing and the foreign body response. Thromb Haemost 90(6):986–992PubMed Kyriakides TR, Bornstein P (2003) Matricellular proteins as modulators of wound healing and the foreign body response. Thromb Haemost 90(6):986–992PubMed
22.
go back to reference Ehrchen J, Heuer H, Sigmund R, Schafer MK, Bauer K (2001) Expression and regulation of osteopontin and connective tissue growth factor transcripts in rat anterior pituitary. J Endocrinol 169(1):87–96PubMedCrossRef Ehrchen J, Heuer H, Sigmund R, Schafer MK, Bauer K (2001) Expression and regulation of osteopontin and connective tissue growth factor transcripts in rat anterior pituitary. J Endocrinol 169(1):87–96PubMedCrossRef
23.
go back to reference Tarin D, Matsumura Y (1993) Deranged activity of the CD44 gene and other loci as biomarkers for progression to metastatic malignancy. J Cell Biochem Suppl 17G:173–185PubMedCrossRef Tarin D, Matsumura Y (1993) Deranged activity of the CD44 gene and other loci as biomarkers for progression to metastatic malignancy. J Cell Biochem Suppl 17G:173–185PubMedCrossRef
24.
go back to reference Weis SM, Cheresh DA (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 17(11):1359–1370PubMedCrossRef Weis SM, Cheresh DA (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 17(11):1359–1370PubMedCrossRef
25.
go back to reference Bornstein P, Sage EH (2002) Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 14(5):608–616PubMedCrossRef Bornstein P, Sage EH (2002) Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 14(5):608–616PubMedCrossRef
26.
go back to reference Goodison S, Tarin D (1998) Clinical implications of anomalous CD44 gene expression in neoplasia. Front Biosci 3:e89–e109PubMed Goodison S, Tarin D (1998) Clinical implications of anomalous CD44 gene expression in neoplasia. Front Biosci 3:e89–e109PubMed
27.
go back to reference Suzuki M, Mose E, Galloy C, Tarin D (2007) Osteopontin gene expression determines spontaneous metastatic performance of orthotopic human breast cancer xenografts. Am J Pathol 171(2):682–692PubMedCrossRef Suzuki M, Mose E, Galloy C, Tarin D (2007) Osteopontin gene expression determines spontaneous metastatic performance of orthotopic human breast cancer xenografts. Am J Pathol 171(2):682–692PubMedCrossRef
28.
go back to reference Lim PK, Bliss SA, Patel SA et al (2011) Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res 71(5):1550–1560PubMedCrossRef Lim PK, Bliss SA, Patel SA et al (2011) Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res 71(5):1550–1560PubMedCrossRef
29.
go back to reference Musumeci M, Coppola V, Addario A et al (2011) Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene 30(41):4231–4242PubMedCrossRef Musumeci M, Coppola V, Addario A et al (2011) Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene 30(41):4231–4242PubMedCrossRef
30.
go back to reference Sugino T, Gorham H, Yoshida K et al (1996) Progressive loss of CD44 gene expression in invasive bladder cancer. Am J Pathol 149(3):873–882PubMed Sugino T, Gorham H, Yoshida K et al (1996) Progressive loss of CD44 gene expression in invasive bladder cancer. Am J Pathol 149(3):873–882PubMed
31.
go back to reference Barnhill RL (2006) The Spitzoid lesion: rethinking Spitz tumors, atypical variants, ‘Spitzoid melanoma’ and risk assessment. Mod Pathol 19(Suppl 2):S21–S33PubMedCrossRef Barnhill RL (2006) The Spitzoid lesion: rethinking Spitz tumors, atypical variants, ‘Spitzoid melanoma’ and risk assessment. Mod Pathol 19(Suppl 2):S21–S33PubMedCrossRef
32.
go back to reference Esserman L, Shieh Y, Thompson I (2009) Rethinking screening for breast cancer and prostate cancer. JAMA 302(15):1685–1692PubMedCrossRef Esserman L, Shieh Y, Thompson I (2009) Rethinking screening for breast cancer and prostate cancer. JAMA 302(15):1685–1692PubMedCrossRef
33.
go back to reference Sanders ME, Schuyler PA, Dupont WD, Page DL (2005) The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 103(12):2481–2484PubMedCrossRef Sanders ME, Schuyler PA, Dupont WD, Page DL (2005) The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 103(12):2481–2484PubMedCrossRef
34.
go back to reference Nickerson HJ, Matthay KK, Seeger RC et al (2000) Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children’s Cancer Group study. J Clin Oncol 18(3):477–486PubMed Nickerson HJ, Matthay KK, Seeger RC et al (2000) Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children’s Cancer Group study. J Clin Oncol 18(3):477–486PubMed
35.
go back to reference Price JE, Carr D, Jones LD, Messer P, Tarin D (1982) Experimental analysis of factors affecting metastatic spread using naturally occurring tumours. Invasion Metastasis 2(2):77–112PubMed Price JE, Carr D, Jones LD, Messer P, Tarin D (1982) Experimental analysis of factors affecting metastatic spread using naturally occurring tumours. Invasion Metastasis 2(2):77–112PubMed
36.
go back to reference Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet i:571–573 Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet i:571–573
37.
go back to reference Tarin D, Price JE, Kettlewell MG, Souter RG, Vass AC, Crossley B (1984) Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res 44(8):3584–3592PubMed Tarin D, Price JE, Kettlewell MG, Souter RG, Vass AC, Crossley B (1984) Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res 44(8):3584–3592PubMed
38.
go back to reference Tarin D, Price JE (1981) Influence of microenvironment and vascular anatomy on “metastatic” colonization potential of mammary tumors. Cancer Res 41(9 Pt 1):3604–3609PubMed Tarin D, Price JE (1981) Influence of microenvironment and vascular anatomy on “metastatic” colonization potential of mammary tumors. Cancer Res 41(9 Pt 1):3604–3609PubMed
39.
go back to reference Hart IR, Fidler IJ (1980) Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res 40(7):2281–2287PubMed Hart IR, Fidler IJ (1980) Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res 40(7):2281–2287PubMed
40.
go back to reference Suzuki M, Mose ES, Montel V, Tarin D (2006) Dormant cancer cells retrieved from metastasis-free organs regain tumorigenic and metastatic potency. Am J Pathol 169(2):673–681PubMedCrossRef Suzuki M, Mose ES, Montel V, Tarin D (2006) Dormant cancer cells retrieved from metastasis-free organs regain tumorigenic and metastatic potency. Am J Pathol 169(2):673–681PubMedCrossRef
41.
go back to reference Goodison S, Kawai K, Hihara J et al (2003) Prolonged dormancy and site-specific growth potential of cancer cells spontaneously disseminated from nonmetastatic breast tumors as revealed by labeling with green fluorescent protein. Clin Cancer Res 9(10 Pt 1):3808–3814PubMed Goodison S, Kawai K, Hihara J et al (2003) Prolonged dormancy and site-specific growth potential of cancer cells spontaneously disseminated from nonmetastatic breast tumors as revealed by labeling with green fluorescent protein. Clin Cancer Res 9(10 Pt 1):3808–3814PubMed
42.
go back to reference Tarin D (1976) Cellular interactions in neoplasia. In: Weiss L (ed) Fundamental aspects of metastasis. North Holland Publishing Co, Amsterdam, pp 151–187 Tarin D (1976) Cellular interactions in neoplasia. In: Weiss L (ed) Fundamental aspects of metastasis. North Holland Publishing Co, Amsterdam, pp 151–187
43.
go back to reference Yasunaga M, Manabe S, Tarin D, Matsumura Y (2011) Cancer-stroma targeting therapy by cytotoxic immunoconjugate bound to the collagen 4 network in the tumor tissue. Bioconjug Chem 22(9):1776–1783PubMed Yasunaga M, Manabe S, Tarin D, Matsumura Y (2011) Cancer-stroma targeting therapy by cytotoxic immunoconjugate bound to the collagen 4 network in the tumor tissue. Bioconjug Chem 22(9):1776–1783PubMed
44.
go back to reference Horak E, Darling DL, Tarin D (1986) Analysis of organ-specific effects on metastatic tumor formation by studies in vitro. J Natl Cancer Inst 76(5):913–922PubMed Horak E, Darling DL, Tarin D (1986) Analysis of organ-specific effects on metastatic tumor formation by studies in vitro. J Natl Cancer Inst 76(5):913–922PubMed
45.
go back to reference Nicolson GL, Dulski KM (1986) Organ specificity of metastatic tumor colonization is related to organ-selective growth properties of malignant cells. Int J Cancer 38(2):289–294PubMedCrossRef Nicolson GL, Dulski KM (1986) Organ specificity of metastatic tumor colonization is related to organ-selective growth properties of malignant cells. Int J Cancer 38(2):289–294PubMedCrossRef
46.
go back to reference Attwood HD, Park WW (1961) Embolism to the lungs by trophoblast. J Obstet Gynaecol Br Commonw 68:611–617PubMedCrossRef Attwood HD, Park WW (1961) Embolism to the lungs by trophoblast. J Obstet Gynaecol Br Commonw 68:611–617PubMedCrossRef
47.
go back to reference Carstens PH (1969) Pulmonary bone marrow embolism following external cardiac massage. Acta Pathol Microbiol Scand 76(4):510–514PubMedCrossRef Carstens PH (1969) Pulmonary bone marrow embolism following external cardiac massage. Acta Pathol Microbiol Scand 76(4):510–514PubMedCrossRef
48.
go back to reference Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883–899PubMedCrossRef Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883–899PubMedCrossRef
50.
51.
go back to reference Ekbom A, Helmick C, Zack M, Adami HO (1990) Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323(18):1228–1233PubMedCrossRef Ekbom A, Helmick C, Zack M, Adami HO (1990) Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323(18):1228–1233PubMedCrossRef
52.
go back to reference Kudo Y, Kamisawa T, Anjiki H, Takuma K, Egawa N (2011) Incidence of and risk factors for developing pancreatic cancer in patients with chronic pancreatitis. Hepatogastroenterology 58(106):609–611PubMed Kudo Y, Kamisawa T, Anjiki H, Takuma K, Egawa N (2011) Incidence of and risk factors for developing pancreatic cancer in patients with chronic pancreatitis. Hepatogastroenterology 58(106):609–611PubMed
53.
54.
go back to reference Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7(3):211–217PubMedCrossRef Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7(3):211–217PubMedCrossRef
55.
go back to reference Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR (2011) Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR (2011) Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol
56.
go back to reference Wyckoff JB, Wang Y, Lin EY et al (2007) Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 67(6):2649–2656PubMedCrossRef Wyckoff JB, Wang Y, Lin EY et al (2007) Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 67(6):2649–2656PubMedCrossRef
57.
go back to reference Nash JR, Price JE, Tarin D (1981) Macrophage content and colony-forming potential in mouse mammary carcinomas. Br J Cancer 43(4):478–485PubMedCrossRef Nash JR, Price JE, Tarin D (1981) Macrophage content and colony-forming potential in mouse mammary carcinomas. Br J Cancer 43(4):478–485PubMedCrossRef
58.
go back to reference Shree T, Olson OC, Elie BT et al (2011) Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev 25(23):2465–2479PubMedCrossRef Shree T, Olson OC, Elie BT et al (2011) Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev 25(23):2465–2479PubMedCrossRef
59.
go back to reference Theoharides TC, Conti P (2004) Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol 25(5):235–241PubMedCrossRef Theoharides TC, Conti P (2004) Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol 25(5):235–241PubMedCrossRef
60.
go back to reference Mahmoud SM, Paish EC, Powe DG et al (2011) Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29(15):1949–1955PubMedCrossRef Mahmoud SM, Paish EC, Powe DG et al (2011) Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29(15):1949–1955PubMedCrossRef
61.
go back to reference Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR (2011) The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR (2011) The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat
62.
go back to reference Mahmoud SM, Paish EC, Powe DG et al (2011) An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res Treat 127(1):99–108PubMedCrossRef Mahmoud SM, Paish EC, Powe DG et al (2011) An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res Treat 127(1):99–108PubMedCrossRef
63.
go back to reference Talmadge JE (2011) Immune cell infiltration of primary and metastatic lesions: mechanisms and clinical impact. Semin Cancer Biol 21(2):131–138PubMedCrossRef Talmadge JE (2011) Immune cell infiltration of primary and metastatic lesions: mechanisms and clinical impact. Semin Cancer Biol 21(2):131–138PubMedCrossRef
64.
go back to reference Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6):442–454PubMedCrossRef Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6):442–454PubMedCrossRef
65.
go back to reference Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871–890PubMedCrossRef Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871–890PubMedCrossRef
66.
go back to reference Hugo H, Ackland ML, Blick T et al (2007) Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J Cell Physiol 213(2):374–383PubMedCrossRef Hugo H, Ackland ML, Blick T et al (2007) Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J Cell Physiol 213(2):374–383PubMedCrossRef
67.
go back to reference Tarin D, Thompson EW, Newgreen DF (2005) The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 65(14):5996–6000, discussion -1PubMedCrossRef Tarin D, Thompson EW, Newgreen DF (2005) The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 65(14):5996–6000, discussion -1PubMedCrossRef
68.
go back to reference Tarin D (2011) Inappropriate gene expression in cancer and its far reaching clinical and biological significance. Canc Metastasis Rev Tarin D (2011) Inappropriate gene expression in cancer and its far reaching clinical and biological significance. Canc Metastasis Rev
69.
go back to reference Domagala W, Wozniak L, Lasota J, Weber K, Osborn M (1990) Vimentin is preferentially expressed in high-grade ductal and medullary, but not in lobular breast carcinomas. Am J Pathol 137(5):1059–1064PubMed Domagala W, Wozniak L, Lasota J, Weber K, Osborn M (1990) Vimentin is preferentially expressed in high-grade ductal and medullary, but not in lobular breast carcinomas. Am J Pathol 137(5):1059–1064PubMed
70.
go back to reference Kubiak RS, Szadowska A (1997) Invasive lobular carcinoma of the breast: correlations between morphological features, vimentin expression, oestrogen receptor status and prognosis. Breast 6:89–96CrossRef Kubiak RS, Szadowska A (1997) Invasive lobular carcinoma of the breast: correlations between morphological features, vimentin expression, oestrogen receptor status and prognosis. Breast 6:89–96CrossRef
71.
go back to reference Domagala W, Markiewski M, Kubiak R, Bartkowiak J, Osborn M (1993) Immunohistochemical profile of invasive lobular carcinoma of the breast: predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive. Virchows Arch A Pathol Anat Histopathol 423(6):497–502PubMedCrossRef Domagala W, Markiewski M, Kubiak R, Bartkowiak J, Osborn M (1993) Immunohistochemical profile of invasive lobular carcinoma of the breast: predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive. Virchows Arch A Pathol Anat Histopathol 423(6):497–502PubMedCrossRef
72.
go back to reference Slack NH, Bross ID (1975) The influence of site of metastasis on tumour growth and response to chemotherapy. Br J Cancer 32(1):78–86PubMedCrossRef Slack NH, Bross ID (1975) The influence of site of metastasis on tumour growth and response to chemotherapy. Br J Cancer 32(1):78–86PubMedCrossRef
73.
go back to reference Fidler IJ, Wilmanns C, Staroselsky A, Radinsky R, Dong Z, Fan D (1994) Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metastasis Rev 13(2):209–222PubMedCrossRef Fidler IJ, Wilmanns C, Staroselsky A, Radinsky R, Dong Z, Fan D (1994) Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metastasis Rev 13(2):209–222PubMedCrossRef
74.
go back to reference Hahn ME, Gianneschi NC (2011) Enzyme-directed assembly and manipulation of organic nanomaterials. Chem Commun (Camb) 47(43):11814–11821CrossRef Hahn ME, Gianneschi NC (2011) Enzyme-directed assembly and manipulation of organic nanomaterials. Chem Commun (Camb) 47(43):11814–11821CrossRef
75.
go back to reference US FaDA (2011) FDA Briefing document Oncology Drug [sic] Advisory Committee Meeting. December 5, 2007. BLA STN 125085/91.018. Avastin (bevacizumab). In US FaDA (2011) FDA Briefing document Oncology Drug [sic] Advisory Committee Meeting. December 5, 2007. BLA STN 125085/91.018. Avastin (bevacizumab). In
76.
go back to reference Pollack A (2011) F.D.A. Revokes approval of avastin for use as breast cancer drug. New York Times 2011 18th November, Sect. B1 Pollack A (2011) F.D.A. Revokes approval of avastin for use as breast cancer drug. New York Times 2011 18th November, Sect. B1
77.
go back to reference Haines IE, Gabor Miklos G (2011) Time to mandate data release and independent audits for all clinical trials. Med J Aust 195(10):575–577PubMedCrossRef Haines IE, Gabor Miklos G (2011) Time to mandate data release and independent audits for all clinical trials. Med J Aust 195(10):575–577PubMedCrossRef
78.
go back to reference Patocs A, Zhang L, Xu Y et al (2007) Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 357(25):2543–2551PubMedCrossRef Patocs A, Zhang L, Xu Y et al (2007) Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 357(25):2543–2551PubMedCrossRef
79.
go back to reference Akino T, Hida K, Hida Y et al (2009) Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors. Am J Pathol 175(6):2657–2667PubMedCrossRef Akino T, Hida K, Hida Y et al (2009) Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors. Am J Pathol 175(6):2657–2667PubMedCrossRef
80.
go back to reference Sumida T, Kitadai Y, Shinagawa K et al (2011) Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model. Int J Cancer 128(9):2050–2062PubMedCrossRef Sumida T, Kitadai Y, Shinagawa K et al (2011) Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model. Int J Cancer 128(9):2050–2062PubMedCrossRef
Metadata
Title
Clinical and Biological Implications of the Tumor Microenvironment
Author
David Tarin
Publication date
01-08-2012
Publisher
Springer Netherlands
Published in
Cancer Microenvironment / Issue 2/2012
Print ISSN: 1875-2292
Electronic ISSN: 1875-2284
DOI
https://doi.org/10.1007/s12307-012-0099-6

Other articles of this Issue 2/2012

Cancer Microenvironment 2/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine